The botulinum neurotoxin (BoNT) family consists of seven antigenically distinct serotypes, BoNT/A to BoNT/G, which act on the peripheral nervous system (19) . Of these toxins, serotypes A, B, E, and F cause botulism in humans, a disease characterized by flaccid muscular paralysis. The neurotoxins are produced as single inactive polypeptides of 150 kDa, which are subsequently processed by proteolytic cleavage into biologically active di-chains (19) . These forms consist of an approximately 50-kDa light chain (LC) linked by a disulfide bridge to a 100-kDa heavy chain (HC) that contains two domains, designated the binding and translocation domains. The neurotoxins reach their intracellular targets by translocating the LC into the cytosol after endocytosis via interaction of the HC with a high-affinity membrane-bound receptor complex (9, 20) . The LC, which possesses a highly specific zinc-endopeptidase activity (29) , then blocks the fusion of synaptic vesicles with the presynaptic membrane by selectively cleaving one of the three polypeptides involved in neuroexocytosis. BoNT/A, for instance, cleaves the 206-amino-acid, 25-kDa synaptosome-associated protein exclusively between the Q 197 and R 198 residues, thus inhibiting neurotransmitter release at the neuromuscular junction (37, 38) .
BoNT/A is recognized as the most toxic serotype; its oral 50% lethal dose (LD 50 ) for humans is estimated at 1 g/kg of body weight (2) . Because of this extreme toxicity and prolonged effect, BoNTs are classified by the Centers for Disease Control and Prevention (CDC) as one of the six highest-risk threat agents for bioterrorism in "category A" (27) . In spite of this, BoNT/A and -B are widely used as therapeutic agents for the treatment of muscular and nerve disorders, as well as in the treatment of neurological diseases (14, 15, 28) . There is also an increasing use of BoNT/A in esthetics for wrinkle reduction (4) . Because of their high toxicity, BoNTs are used at very low concentrations, and procedures to be used for their detection and quantification in toxin preparations for medical applications or in the event of malevolent bioterrorist acts have to be highly sensitive, rapid, and easy to use; the use of all lengthy in vivo assays is excluded (2, 11) . The advantage of the currently used pharmacotoxicological mouse LD 50 (MLD 50 ) assay, considered the gold standard assay, is that it provides the in vivo toxicity of a given botulinum toxin sample, whatever the nature of the infected medium. However, this assay is time-consuming, requires the use of a large number of animals, and has poor repeatability due to many fluctuant parameters involved in this method (22) . Several in vitro assays have been reported for the detection of BoNT/A, relying either on mass spectrometry (3, 16) , immunological detection (10, 25) , or BoNT/A's endopeptidase activity (12, 30) . The advantage of the endopeptidase assay is that it measures and quantifies the "active" part of the toxin, which is directly responsible for neurotransmission inhibition. Various methods have been developed to quantify the BoNT/A proteolytic activity (12, 23, (32) (33) . Although some of these assays are very sensitive (11) , they cannot be used for the field detection of BoNT/A, as they require a multistep procedure, and they are also not easily amenable to quantification of toxin preparations used for medical applications.
In this paper, we have designed novel, specific, high-affinity, mimetic peptide substrates for BoNT/A using the internalcollision-induced fluorescence-quenching technique (13) . This technique, the use of which has previously been successful in the design of peptide substrates for other Zn-metallopeptidases, e.g., ECE-1 (18) and BoNT/B (1, 26) , involves the introduction of a fluorophore/repressor pair, here the highly fluorescent pyrenylalanine (Pya) along with a nitro-phenylalanine (Nop) repressor residue on each side of the cleavage site. Once the better positions of the fluorophore/repressor pair Pya/Nop were determined using a fragment of the SNAP-25 sequence from amino acids 187 to 203 [(187-203 , respectively. The use of these novel high-affinity substrates provides a simple, one-step, specific, robust, and rapid enzymatic assay, thus fulfilling all the requirements for BoNT/A field detection and for BoNT/A's quantification in preparations for medical applications.
MATERIALS AND METHODS
Peptide synthesis. 9-Fluorenylmethoxy carbonyl (Fmoc) amino acids and coupling reagents were purchased from Applied Biosystems (Courtaboeuf, France). Fmoc-L-(para nitro)-phenylalanine was from Bachem Distribution (Germany), and Fmoc-L-pyrenylalanine was from Polypeptides (Strasbourg, France). HMP (4-hydroxymethylphenoxyacetyl-4Ј-methylbenzyhydrylamine) and MBHA (methylbenzhydrylamine) resins were from Novabiochem (VWR, Fontenay sous Bois, France), and all the solvents were from Carlo Erba-SDS (Vitry, France).
Peptides were synthesized by the solid-phase method, with an ABI 433A Applied Biosystems automated synthesizer, coupled to a model 785A programmable absorbance UV detector. The synthesis was carried out using the classical Fmoc protocol with HBTU [O-(benzotriazol-1-yl)-N,N,NЈ,NЈ-tetramethyluronium hexafluorophosphate], HOBt (1-hydroxybenzotriazole), and diisopropylethylamine as coupling reagents. By this strategy, the amino acid side chains were protected by a t-butyl group, except Asn, Cys, Gln, and His, which were protected by a trityl group, Trp, which was protected by a t-butoxy group, and Arg, which was protected by a Pmc (2,2,5,7,8-pentamethylchroman-6-sulfonyl) group.
The synthesis of the various SNAP-25 fragments was performed at a 100 M scale on an MBHA resin for the peptides bearing a carboxamide at their C termini and on an HMP resin for those having a free carboxylate group, using a precharged resin for the first amino acid.
All peptides, except those corresponding to the C-terminal metabolites, were acetylated at the end of the synthesis at their N-terminal amino group by action of acetic anhydride in N-methylpyrrolidone for 30 min. The peptidyl resin was treated with a solution of trifluoroacetic acid (TFA), phenol, triisopropylsilane (TIPS), and H 2 O (90:5:2.5:2.5) for the cleavage of both the resin and side chain protections. After filtration of the resin, the solution was evaporated under vacuum and the residue precipitated in cold diethyl ether. Peptides were purified by semipreparative reversed-phase chromatography (Waters) on a Kromasil C 18 column (10 by 250 mm, 5-mm inside diameter,100 Å) with different gradients of CH 3 CN-H 2 O (0.05% TFA) at a flow rate of 10 ml/min with UV-spectrophotometric monitoring at wavelengths of 210 and 343 nm. The fractions were analyzed by reversed-phase high-performance liquid chromatography (HPLC) (Shimadzu) on a Kromasil C 18 column (4.6 by 250 mm, 5-m inside diameter, 100 Å) at a flow rate of 1 ml/min with monitoring at both 210 and 343 nm. Unless indicated, HPLC analysis were performed using a Kromasil C 18 column with a 10% CH 3 CN-90% H 2 O (0.1% TFA) to 90% CH 3 CN-10% H 2 O (0.1% TFA) elution gradient in 30 min. The purity of the peptides determined by HPLC was found to be greater than 98.5%, and their molecular weights (MWs) were confirmed by deconvolution of the mass spectra obtained with an electrospray mass spectrometer (Thermo Finnigan) using Xcalibur software.
The 
min).
BoNT/A purification. BoNT/A was produced and purified from Clostridium botulinum (A/B) strain NCTC2916 as previously described (34) . Briefly, C. botulinum was grown in TGY (Trypticase, 30 g/liter; yeast extract, 20 g/liter; glucose, 5 g/liter; cysteine chlorhydrate, 0.05 g/liter; pH 7.5) for 4 days at 37°C under anaerobic conditions. The culture was precipitated at pH 3.5 with sulfuric acid. The precipitate was collected by centrifugation and extracted with 0.2 M sodium phosphate buffer (pH 6). After centrifugation, the supernatant was precipitated with ammonium sulfate (39 g/100 ml). The precipitate was suspended in distilled water, dialyzed against 50 mM sodium citrate, pH 5.4, and loaded onto a QAE-
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Sepharose column (Amersham) equilibrated with the same buffer. The flowthrough and the 0.15 M NaCl eluate were precipitated with ammonium sulfate (39 g/100 ml), dialyzed against Tris-HCl 10 mM, pH 8.2, and loaded onto a QAE-Sepharose column equilibrated with the same buffer. The column was eluted using a 0-to-0.15 M NaCl gradient in the same buffer. The fractions containing BoNT/A as evidenced by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were pooled, concentrated, and stored in aliquots at Ϫ80°C. Toxin quantification. For densitometric quantification of the purified BoNT/A, the stock solution (5 l) was diluted in sample loading buffer (0.1 M Tris-HCl, pH 6.8, 15% glycerol, 3% SDS, and 0.02% bromophenol blue), loaded onto a 10% polyacrylamide gel, and subjected to SDS-PAGE in parallel with at least three concentrations of bovine serum albumin (BSA). Proteins were stained with Coomassie brilliant blue R-250 (Bio-Rad). The stained gel was subjected to densitometric analysis using the Quantity One software (Bio-Rad), and BoNT/A was quantified using BSA standards.
MLD 50 determinations. Male Swiss mice (18 to 24 g; Charles River) were used in these experiments. The BoNT/A stock solution was diluted appropriately in sterile phosphate buffer (50 mM, pH 6.3, 0.2% gelatin). The toxin solutions (0.5 ml) were administered intraperitoneally and the mice observed for 4 days.
In a preliminary experiment, six dilutions of BoNT/A ranging from 10 Ϫ4 to 10 Ϫ9 of the stock solution were administered to two mice per dose and the mortality rate was recorded after 4 days. Based on the results of this preliminary experiment, a second experiment was performed with dilutions ranging from 5.0 ϫ 10 Ϫ7 to 7.8 ϫ 10 Ϫ9 , using groups of four mice. The death rate was again recorded 4 days after injection. Based on the obtained results, the toxicity of the injected solution was quantified according to the following formula: toxicity ϭ (1/dilution) ⅐ (LD 50 /V), where V is the injected volume.
Substrate solubilization. Because of their low solubility in water, peptide stock solutions (100 or 500 M) were prepared in 50:50 (vol/vol) dimethylformamide (DMF) and H 2 O. The subsequent working dilutions were then made in the appropriate assay buffer. Under optimized conditions, 100 M peptide stock solutions were made in 15:
Spectrophotometric measurements. UV absorption spectra of the various substrates and metabolites (0.25 M in assay buffer with 5% DMF) were recorded on a Shimadzu UV mini 1240 spectrophotometer. Spectrofluorimetric measurements were performed on a PerkinElmer LS50B spectrometer equipped with a thermostated cell holder.
HPLC analysis of peptide cleavage. The hydrolysis of PL50 (15 M) by 10 ng/ml of toxin was studied by HPLC after a 5-h incubation at 37°C in standard assay buffer (20 mM HEPES buffer, pH 7.4, containing 5 mM dithiothreitol [DTT], 0.2 mM ZnSO 4 , and 1 mg/ml BSA). At the end of the incubation, the hydrolysis products were loaded onto a Kromasil C 18 column (4.6 by 250 mm, 5-m inside diameter, 100 Å) and separated using a 10-to-90% CH 3 CN (0.1% TFA) gradient in 30 min with a flow rate of 1 ml/min. The detection was performed with UV at 343 nm. The same experiment was also performed using the PL51 substrate. The nature of the observed metabolites was confirmed by coinjections with pure synthetic compounds as well as by mass spectrometry analysis.
Fluorimetric enzymatic assays for BoNT/A quantification. The various peptide substrates were tested in enzymatic assays using purified BoNT/A based on a protocol previously described by Schmidt and Bostian (30, 31) . Briefly, the purified 150-kDa toxin was preincubated in 20 mM HEPES buffer, pH 7.4, containing 5 mM DTT, 0.2 mM ZnSO 4 , and 1 mg/ml BSA for 30 min at 37°C to separate the LC from the HC. The enzymatic reaction was then initiated by the addition of the peptide substrate, and the incubation was performed at 37°C for 1 to 5 h. The experiments were performed using a multiwell microplate reader fluorimeter (Twinkle LB 970; Berthold Technologies) in a total volume of 100 l. The fluorescence was measured every 15 min at an excitation wavelength of 340 nm and an emission wavelength ( em ) of 405 nm (lamp energy, 10,000). Negative controls without toxin were also included in every experiment. All measurements were performed in duplicate in at least two independent experiments.
For the peptides derived from the (187-203) SNAP-25 fragment (peptides 8 and 9), kinetic parameters were determined using 100 ng/ml of purified BoNT/A in assay buffer, with peptide concentrations ranging from 1 to 50 M and with incubation for 1 h at 37°C. Determination of the kinetic parameters of the longer peptides derived from the (156-203) SNAP-25 fragment (peptides 10 and 11 or PL50 and -51) were performed using 10 ng/ml of BoNT/A and peptide concentrations ranging from 1 to 5 or 10 M, with incubation for 30 min at 37°C. Calibration curves connecting the increase in fluorescence intensity to changes in the molar ratio of the substrate to the metabolite were established in assay buffer by mixing increasing concentrations of the fluorescent metabolite and related decreasing concentrations of the substrate.
Optimization of the assay conditions involved testing the effects of various reducing agents, i.e., dithioerythritol or Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), at different concentrations between 1 and 10 mM on the fluorescent signal produced by the toxin. The effect of removing BSA from the assay buffer was also investigated. (Fig. 2) . The basal levels of fluorescence of peptides 7 and 8 (20 M) in assay buffer were not significantly different from one another (110 arbitrary units [AU] and 75 AU, respectively) showing equivalent quenching efficiencies. After a 3-h incubation with BoNT/A (50 ng/ml), the cleavage of peptide 7 produced a fluorescence increase of 176 AU, while cleavage of peptide 8 led to a much greater increase of 1,100 AU (Fig. 2) .
RESULTS

Design
This result was confirmed by HPLC analysis of the incubation medium performed with UV detection at a of 343 nm, a R 198 , revealing that the presence of the nonnatural residues in the synthetic peptides did not change the cleavage site observed in native SNAP-25. Moreover, the fact that only two metabolites were formed indicated that the high specificity of BoNT/A was preserved in this minimal sequence (see Fig. S1 in the supplemental material).
Based on these results, peptide 8 was selected as the first "lead" in the search for an efficient fluorigenic substrate for BoNT/A, and its kinetic parameters were determined. The affinity (K m ) of the peptide toward BoNT/A was 13 Ϯ 3 M, whereas its k cat was 0.79 Ϯ 0.06 s Ϫ1 , leading to a catalytic efficiency (k cat /K m ) of (6.1 Ϯ 0.5) ϫ 10 4 M Ϫ1 s Ϫ1 (Table 2; Design and properties of fluorescently quenched substrates based on the sequence of (156-203) SNAP-25. To further improve the sensitivity and velocity of the BoNT/A fluorescence assay, we took into account the demonstrated presence of BoNT/A exosites able to bind BoNT/A's substrate at a more or less great distance from the scissile bond, thus positively impacting its cleavage (5, 8) . Consequently, the fluorophore/repressor pair Pya/Nop was introduced into the (156-203) SNAP-25 fragment at the previously determined optimal positions in peptides 8 and 9, i.e., at positions 197 for Nop and 200 for Pya, to yield peptide 10.
Finally, the sequence of peptide 10, or PL50 (Ac-IIGNLR HMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANNop-RA-Pya-K-Nle-L-NH 2 ) was modified to increase its stability. To prevent their possible oxidation, the three Met residues at positions 153, 157, and 172 of peptide 10 were replaced by their isosteric analogue, Nle, leading to peptide 11, or PL51 (Ac-IIGNLRH-Nle-ALD-Nle-GNEIDTQNRQIDRI-Nle-EKADSNKTRIDEAN-Nop-RA-Pya-K-Nle-L-NH 2 ).
Spectral properties of PL50 and PL51. The UV spectra of peptide 10 (PL50) and of its fluorescent metabolite R-A-Pya-K-Nle-L-NH 2 (peptide 12) reveal wavelengths of maximum absorption at 343.5 nm (ε mol ϭ 29,750 liters ⅐ mol Ϫ1 cm Ϫ1 ) and at 342.5 nm (ε mol ϭ 27,500 liters ⅐ mol Ϫ1 cm Ϫ1 ), respectively, showing that the chemical environment of the fluorophore has only a slight effect on the absorption maximum but a significant effect on the molar absorption.
The fluorescence spectra obtained for these compounds after excitation at 343 nm display two maxima at em s of 378 and 398 nm (Fig. 3) . The superimposition of the emission spectra of peptide 10 and of its fluorescent metabolite (peptide 12) at To determine the fluorescence ratio between peptide 11 (PL51) and its fluorescent metabolite (peptide 12), the former compound was used at 10 M and the latter at 0.25 M (2.5% degradation). The fluorescence intensities measured at 378 nm for both peptides, for which identical concentrations were extrapolated, gave a quenching factor of 150 (not shown).
Cleavage site determination and kinetic parameters of PL50 and PL51. HPLC analysis of the cleavage products of PL50 by BoNT/A shows the appearance of two chemical entities at 210 nm (not shown), only one of which was detected at 343 nm (UV absorption of Pya) or with a fluorimetric detector ( em ϭ 377 nm) (Fig. 4) . The Rt of this fluorescent metabolite (13.03 min) corresponded to that of peptide 12 (RA-Pya-K-Nle-L-NH 2 ). The second nonfluorescent metabolite had an Rt of 14.6 min and was shown by coinjection to correspond to the Nterminal synthetic peptide (156-197) SNAP-25 (Nop 197 ), or peptide 16. The same results were observed with PL51, whose cleavage by BoNT/A also led to only two metabolites, one corresponding to peptide 17 and the other to fluorescent peptide 12 (not shown).
The kinetic parameters of PL50 were determined and are reported in Table 2 (see also Fig. S2 in the supplemental material). The K m value was 0.79 Ϯ 0.20 M, and the k cat value was 2.08 Ϯ 0.12 s Ϫ1 , leading to a k cat /K m of 2.63 ϫ 10 6 Ϯ 0.15 ϫ 10 6 M Ϫ1 s Ϫ1 . Thus, the k cat value of PL50 was increased by a factor 2 compared to that of peptide 9, while its apparent affinity was improved by a factor 10. Finally, while the k cat value of PL51 was not improved compared to that of PL50, its apparent affinity was increased sixfold, yielding a better k cat /K m value for this last peptide substrate (K m ϭ 0.13 Ϯ 0.02 M, Table 2 ; Fig. S2 in the supplemental material).
Characterization and calibration of the BoNT/A-PL50 enzymatic assay against the MLD 50 assay. Using PL50, the novel BoNT/A enzymatic assay was characterized. There was a linear correlation between the fluorescent signal and PL50 substrate concentration used in the 1 M-to-10 M range (R 2 ϭ 0.994) (Fig. 5A) . There was also a linear correlation between the fluorescent signal and time over 150 min using a 10 M PL50 substrate concentration and 10 ng/ml of BoNT/A (R 2 ϭ 0.994) (Fig. 5B) . Based on these data, PL50 was used in the assay at a concentration of 10 M. Under these conditions, a detection of 10 ng/ml of the toxin could be obtained in less than 1 h.
In order to calibrate the assay not only versus protein weight but also versus the commonly accepted unit concentration, it was necessary to be able to convert one scale into another. As units, in the case of toxins, correspond to MLD 50 values, we performed an MLD 50 assay using our stock solution of purified toxin. For this purpose, the stock solution was serially diluted, and on the same day, dilutions were either injected into mice intraperitoneally (5 ϫ 10 Ϫ7 to 7.81 ϫ 10 Ϫ9 ) to determine the MLD 50 or used in the fluorescent PL50 enzymatic assay (0.5 ϫ 10 Ϫ3 to 10 Ϫ6 ). The results of a typical MLD 50 assay are presented in Table  3 . Based on these results, the concentration of the purified toxin stock solution was determined to be 1.7 ϫ 10 8 MLD 50 s/ml or U/ml. The same results, combined with the estimated protein concentrations, also allow us to estimate the MLD 50 of the toxin as 1.9 pg (Table 3) .
Using the 0.5 ϫ 10 Ϫ3 , 10 Ϫ4 , 0.5 ϫ 10 Ϫ4 , 10 Ϫ5 , 0.5 ϫ 10 Ϫ5 , and 10 Ϫ6 stock solution dilutions, the BoNT/A enzymatic assay was performed using 10 M PL50. Results of the fluorescent assay reveals that, considering a 100 AU increase in fluorescence as the limit of detection, the lowest concentration of BoNT/A detected using the PL50 enzymatic assay is 2 ng/ml in 120 min or 4 ng/ml in 1 hour. These values correspond to 200 and 400 pg of purified 150-kDa toxin per assay, respectively. Using the results of the MLD 50 assay performed in parallel with the same toxin solution, the detected toxin concentrations can be converted to MLD 50 values. Thus, using 1.9 pg as 1 MLD 50 , the PL50 assay can detect 115 MLD 50 s in 120 min (Fig. 6) .
Sensitivity optimization. One of the aims of this study was to use the developed assay for the detection and quantification of BoNT/A in medical samples which contain between 100 and 500 MLD 50 s. The MLD 50 being estimated at about 2 pg, it was important to detect less than 200 pg in a given sample in the shortest incubation time possible. To increase the sensitivity of the BoNT/A enzymatic assay, the assay conditions were optimized on one hand, and on the other hand, the PL50 substrate was substituted for PL51 in a comparative assay with toxin concentrations of either 0.5, 1, or 2 ng/assay and incubated for 120 min at 37°C. The results depicted in Fig. 7 show that under these optimized conditions, a detection limit of 100 pg of toxin in 120 min, corresponding to 53 MLD 50 s, was obtained. Under the same conditions, the use of PL51 also significantly increased the sensitivity of the assay. Thus, in 120 min using PL51, one can detect around 30 MLD 50 s (Fig. 7) .
DISCUSSION
Intramolecularly quenched fluorescent peptides containing the fluorophore/repressor pair Pya/Nop have successfully been developed for the detection and quantification of various specific enzymatic activities (1, 18) . With these substrates, the observed quenching is attributed to collisional interactions between the side chains of the fluorophore/repressor pair members. The Pya/Nop pair is particularly well adapted due to the high quantum yield and long half-life of the fluorescence of the pyrenyl moiety (Pya) and the low absorption of the quencher residue, (p-NO 2 )-phenylalanine (Nop), at the excitation wavelength of Pya (1). These properties have led to the design of the most-efficient fluorescent substrate of BoNT/B described to date, by the introduction of the Pya and Nop moieties at positions 74 and 77 of synaptobrevin (positions 60 to 94), respectively, i.e., on each side of the neurotoxin scissile bond (26) .
In order to develop a specific and high-affinity substrate for BoNT/A, we first introduced the fluorigenic pair at and around the 197 Q-R 198 cleavage site of SNAP-25 using the previously described 17-mer peptide (187-203) SNAP-25 (30) to optimize the relative positions of the fluorophore/repressor pair. As shown in Table 1 , the presence of the 198 R-A 199 amino acids was absolutely necessary for BoNT/A recognition, and the positions of the Pya and Nop moieties around these amino acids a Evaluation of mouse mortality 4 days postinjection after intraperitoneal injection of successive dilutions of a BoNT/A (150 kDa) stock solution. Based on the toxin concentration evaluated by gel electrophoresis, the toxin concentration corresponding to each toxin dilution is also indicated. From the mouse mortality observations, the potency of the stock solution can be calculated using the formula 1/LD 50 dilution/V (injected volume). If the LD 50 is located at a dilution intermediary between 1.56 ϫ 10 Ϫ8 and 7.81 ϫ 10
Ϫ9
, i.e., 1.17 ϫ 10
Ϫ8
, the potency of the stock solution is 1.7 ϫ 10 8 MLD 50 s/ml. Moreover, the protein concentration corresponding to the MLD 50 dilution can be deduced from the data in the first column, i.e., 3.80 pg/ml, which yields an MLD 50 value of 1.9 pg (injected volume ϭ 0.5 ml). (1) . The introduction of the Pya and Nop residues, both with aromatic side chains, in the vicinity of the BoNT/A cleavage site significantly improved the affinity of the substrate toward the toxin. Indeed, the observed K m of peptide 8 (13 M) was 400-fold better than that of its parent peptide, (187-203) SNAP-25 (K m ϭ 5 mM) (30) . However, these favorable hydrophobic interactions had an adverse effect on the reaction rate, which was significantly decreased using peptide 8 as the substrate (k cat ϭ 0.79 s Ϫ1 ) ( (33) . Although the sensitivity of the assay using the peptide 8 substrate was sufficient for inhibitor screening using high-throughput-screening techniques, it was considered insufficient for the quantification of toxin formulations used for medical purposes.
Clostridial toxins such as the tetanus and botulinum toxins have been shown to possess exosites whose role is to induce an increase in the velocity of the reaction by an allosteric mechanism (5, 8) . Previous analyses of SNAP-25 deletion mutants The first fragment was shown to play an important role in the binding affinity of the peptide toward the toxin, while the second is involved in catalytic efficiency. Moreover, it has been demonstrated that the internal (168-186) SNAP-25 sequence facilitates the binding of SNAP-25 to the toxin, thereby enhancing the cleavage rate (7, 21) . Taken together, these results, strongly suggested that (156-203) SNAP-25 could be optimal for BoNT/A binding. Accordingly, the fluorigenic substrates PL50 (peptide 10) and PL51 (peptide 11), corresponding to this (156-203) SNAP-25 sequence, were designed. The specific activity of the resulting PL50 substrate was found to be 100-fold better than that of peptide 8, resulting exclusively from a significant increase of the apparent affinity of PL50 (Table 2 ; Fig. S2 in the supplemental material) and confirming the hypothesis that increasing peptide length would ameliorate BoNT/A recognition, probably by binding one or more exosites of the BoNT/A LC. Interestingly, PL50 also displays a 50-to 60-fold-higher apparent affinity for BoNT/A than full-length SNAP-25 (K m ϭ 40 to 50 M), while the cleavage rate is not significantly improved (6, 17) .
In an effort to calibrate this novel enzymatic assay against the gold standard, but nonetheless controversial, MLD 50 assay, parallel experiments were performed using the same toxin dilutions. The ensemble of these results shows that the purified toxin used in this study possesses an MLD 50 of 1.9 pg, a value in line with those found in the literature (2) . Moreover, this allows the detection limit of the assay to be expressed either in toxin weight or in MLD 50 s. Thus, as shown in Fig. 6 and 7 , using the PL50 substrate under previously published conditions, the detection limit of the assay was found to be about 115 MLD 50 s. Using TCEP as the reducing agent, the detection limit was lowered by over 50% to 53 MLD 50 s in 120 min, reaching values as low as 15 MLD 50 s in 300 min, providing to date the most sensitive direct assay to measure BoNT/A activity. To protect the PL50 peptide from oxidation, the methionine residues in its sequence were replaced by norleucines, to yield PL51. Interestingly, this substrate possessed a slightly better specificity constant than its parent compound (Table 2) , providing better sensitivity for shorter incubation times, i.e., 32 MLD 50 s in 120 min (Fig. 7) .
Altogether, this study reveals that PL50 and PL51, which associate excellent catalytic efficiencies with the remarkable fluorigenic properties of Pya, are at present the most efficient and easy-to-use fluorescent substrates of BoNT/A (M. C. Fournié-Zaluski and B. P. Roques, 22 December 2005, patent application PCT WO 2005 1121354 A2). The two substrates are therefore of value for measuring the concentration of BoNT/A in medicinal preparations in which the smaller amount of BoNT/A employed corresponds to 50 MLD 50 s. One of the main advantages of this enzymatic assay is that it is a single-step assay which circumvents any specificity problems that can be encountered with other immunoabsorbent enzyme-linked immunosorbent assay-type assays (12, 23, 24) . It can be used to quantify BoNT/A in pharmaceutical toxin preparations and could also find application in the detection of toxin in complex matrices, although its efficacy will be dependent on preliminary extraction methods. This assay also drastically reduces the time necessary to obtain a result, the toxin here being quantified, and identified, within an hour. These are important considerations, particularly in the case of crisis situations where malevolent bioterrorist acts are suspected (e.g., in water systems), and the use of the assay is thus expected to severely reduce the use of the mouse bioassay, which nevertheless remains necessary for investigating the endocytosis property of a given enzymatically active toxin.
